Seattle Genetics, Inc. (SGEN) And Insider Trading Activity

Wednesday, 07 Feb, 2018

The institutional investor held 251,143 shares of the health care company at the end of 2017Q3, valued at $9.09M, down from 266,493 at the end of the previous reported quarter. Prudential Financial reported 0% of its portfolio in Seattle Genetics, Inc. Public Employees Retirement System of OH now owns 143,036 shares of the company's stock worth $3,696,000 after buying an additional 1,480 shares in the last quarter. About 759,105 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since February 5, 2017 and is uptrending.

Huber Capital Management Llc increased Ensco Plc (ESV) stake by 39.68% reported in 2017Q3 SEC filing. Cs Mckee Lp bought 12,650 shares as the company's stock rose 13.21% with the market. The stock decreased 0.64% or $0.115 during the last trading session, reaching $17.885. About 20,413 shares traded. Carter's, Inc. (NYSE:CRI) has declined 16.63% since February 5, 2017 and is downtrending. (NASDAQ:MYGN) earned "Hold" rating by Jefferies on Tuesday, September 12. Therefore 20% are positive. Dycom had 30 analyst reports since August 27, 2015 according to SRatingsIntel. Geode Mngmt Ltd Liability Co reported 12.73 million shares stake. Mizuho has "Neutral" rating and $38 target. The firm has " rating by Jefferies given on Wednesday, April 19. As per Tuesday, August 25, the company rating was maintained by William Blair. H.C. Wainwright maintained the stock with "Buy" rating in Monday, June 19 report. The firm earned "Buy" rating on Monday, November 13 by SunTrust. FBR Capital maintained it with "Outperform" rating and $112 target in Thursday, May 25 report. The firm earned "Hold" rating on Thursday, June 8 by J.P. Morgan.

Since January 29, 2018, it had 0 buys, and 1 insider sale for $2.77 million activity. Sterling Cap Lc has 7,249 shares. (NYSE:T) for 769,560 shares.

Following some medium-term indicators on shares of Thomson Reuters Corporation (TRI), we can see that the 40-day commodity channel index signal is presently Sell while the 50-day Parabolic SAR generates a Sell signal. Also, Director Heinrich Dreismann sold 6,000 shares of Myriad Genetics stock in a transaction on Monday, December 11th. 25,000 shares valued at $1.31 million were sold by DOBMEIER ERIC on Thursday, August 31.

Investors sentiment decreased to 1 in 2017 Q3. Its up 0.02, from 1.15 in 2017Q2. It worsened, as 51 investors sold SGEN shares while 74 reduced holdings. 48 funds opened positions while 97 raised stakes. 202,827 are held by Metropolitan Life Com New York. Qs Invsts Ltd Liability Company has 0% invested in Seattle Genetics, Inc. Davis Ptnrs Ltd Liability has invested 2.82% in JPMorgan Chase & Co. Moreover, Knott David M has 0.39% invested in Apollo Global Management, LLC (NYSE:APO). (NYSE:DY). First Republic Mngmt Inc has 0% invested in Dycom Industries, Inc. Cutter Brokerage has 0.27% invested in JPMorgan Chase & Co.

There are 324 institutional holders with active positions, accounting for 143.03 million shares in total. Eventide Asset Ltd Limited Liability Company has invested 1.62% of its portfolio in Seattle Genetics, Inc. Massachusetts-based Ipswich Invest Management has invested 0.34% in Applied Materials, Inc. (NYSE:JPM). Carderock Management holds 0.93% or 21,604 shares. Smith Salley And reported 2.44% stake.

The average Wall Street analyst rating for Seattle Genetics, Hold, according to the average of 14 analyst scores. Therefore 89% are positive. Carter's had 33 analyst reports since August 31, 2015 according to SRatingsIntel. Piper Jaffray maintained Myriad Genetics, Inc.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The firm has "Hold" rating by Piper Jaffray given on Monday, July 24. Advisors Lp Baker purchased 3,846,153 shares of Seattle Genetics stock in a transaction on Thursday, February 1st. Cantor Fitzgerald set a $46.00 target price on Seattle Genetics and gave the stock a "hold" rating in a report on Tuesday, October 10th. (NYSE:PRU) has "Neutral" rating given on Friday, October 7 by Credit Suisse. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The rating was downgraded by Gabelli to "Hold" on Wednesday, August 10. Myriad Genetics now has a consensus rating of Hold and a consensus target price of $30.67. Barclays Capital maintained the shares of KMB in report on Monday, March 21 with "Overweight" rating. The stock has "Market Perform" rating by Wells Fargo on Wednesday, August 10.

Since September 1, 2017, it had 0 insider buys, and 8 sales for $6.39 million activity.

Seattle Genetics Inc Wa stake is new for [reportingPerson]. (NASDAQ:SGEN) for 6,565 shares. The original version of this piece can be read at (NASDAQ:MYGN) for 17,333 shares. Northern Trust Corp now owns 568,337 shares of the biotechnology company's stock worth $29,406,000 after purchasing an additional 1,994 shares during the period. (NASDAQ:SGEN). Millennium Mngmt Limited Co reported 36,526 shares.

Investors sentiment decreased to 0.86 in 2017 Q3. Its up 0.24, from 0.82 in 2017Q2. 123 funds opened positions while 263 raised stakes. Schwab Charles Investment Mgmt, a California-based fund reported 630,932 shares. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.05. Sei Invests reported 19,518 shares or 0% of all its holdings. Qci Asset Mgmt has 176 shares. Tieton Capital Management Llc who had been investing in Myriad Genetics for a number of months, seems to be less bullish one the $2.50B market cap company. Victory Cap Mgmt accumulated 26,481 shares. Prudential Financial Inc. lifted its holdings in shares of Seattle Genetics by 6.8% in the second quarter. Amalgamated Bank & Trust invested 0.01% of its portfolio in Myriad Genetics, Inc. Credit Agricole S A owns 18,376 shares or 0% of their USA portfolio. Epoch stated it has 0.1% of its portfolio in Carter's, Inc. Ahl Partners Ltd Liability Partnership invested 0.05% in Myriad Genetics, Inc. (NASDAQ:SGEN) for 100 shares. Mackenzie holds 0.04% of its portfolio in Myriad Genetics, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.